Geron Corp. (GERN)

Overview News Price History Option Chain Why GERN Down? Discussions Forecast

Geron Corp. stock is currently priced at $3.73, with a 24-hour trading volume of 9.66M. It has seen a +1.36% increased in the last 24 hours and a +17.48% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $3.70 pivot point. If it approaches the $3.78 resistance level, significant changes may occur.

Geron Corp. Stock (GERN) Financials Data

Geron Corp. (GERN) Revenue 2024

GERN reported a revenue (TTM) of $237.00 thousand for the quarter ending December 31, 2023, a -60.23% decline year-over-year.

Geron Corp. (GERN) Net Income 2024

GERN net income (TTM) was -$184.13 million for the quarter ending December 31, 2023, a -29.76% decrease year-over-year.

Geron Corp. (GERN) Cash Flow 2024

GERN recorded a free cash flow (TTM) of -$168.57 million for the quarter ending December 31, 2023, a -31.89% decrease year-over-year.

Geron Corp. (GERN) Earnings per Share 2024

GERN earnings per share (TTM) was -$0.33 for the quarter ending December 31, 2023, a +8.33% growth year-over-year.

Geron Corp. Stock (GERN) Latest News

Argan Reports Upbeat Earnings, Joins Coupang And Other Big Stocks Moving Higher On Friday

Benzinga

Jim Cramer: This Tech Stock Is 'Great,' Archer Aviation Is 'Too Speculative For Me'

Benzinga

The Latest Analyst Ratings For Geron

Benzinga

Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More

Zacks Investment Research

Company News for Mar 18, 2024

Zacks Investment Research

Why Nuvei Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket

Benzinga

Geron Corporation operates as a biopharmaceutical company. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses. The company was founded in 1990 and is based in Menlo Park, California.

Upgrade	Goldman: Neutral → Buy	Sep-12-23
Initiated	Goldman: Neutral	Mar-28-23
Initiated	Wedbush: Outperform	Oct-28-22
Resumed	B. Riley Securities: Buy	Jul-28-22
Initiated	Robert W. Baird: Outperform	Nov-02-21
Resumed	B. Riley Securities: Buy	Feb-18-21
Initiated	Stifel: Buy	Aug-03-20
Resumed	B. Riley FBR: Buy	Nov-19-19
Initiated	H.C. Wainwright: Buy	Sep-03-19
Initiated	Cantor Fitzgerald: Overweight	Aug-15-19
Upgrade	Needham: Hold → Buy	Apr-09-19
Upgrade	B. Riley FBR: Neutral → Buy	Jan-31-19
Downgrade	B. Riley FBR: Buy → Neutral	Oct-02-18
Initiated	B. Riley FBR, Inc.: Buy	Jul-05-18
Reiterated	FBR & Co.: Outperform	Sep-13-16
Reiterated	FBR Capital: Outperform	Sep-13-16
Reiterated	Piper Jaffray: Overweight	Dec-07-15
Initiated	Oppenheimer: Outperform	Apr-21-15
Upgrade	MLV & Co: Hold → Buy	Jun-12-14
Downgrade	MLV & Co: Buy → Hold	Mar-12-14
Reiterated	MLV & Co: Buy	Dec-10-13
Upgrade	Needham: Hold → Buy	Dec-10-13
Reiterated	MLV & Co: Buy	Nov-08-13
Initiated	MLV & Co: Buy	Oct-16-13
Initiated	Stifel Nicolaus: Buy	Aug-30-12
Initiated	Needham: Hold	Jun-28-12